References

• 2013Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force319 cited
• 2010Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers287 cited
• 2013Managed entry agreements for pharmaceuticals: the European experience167 cited
• 2017Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund162 cited
• 2014Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden156 cited
• 2011What principles should govern the use of managed entry agreements?155 cited
• 2007Coverage with Evidence Development: An examination of conceptual and policy issues147 cited
• 2017Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future142 cited
• 2010Funding the Unfundable132 cited
• 2013Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries122 cited
• 2017The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications122 cited
• 2014Italian risk-sharing agreements on drugs: are they worthwhile?114 cited